copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Altor Bioscience Corporation and NantKwest Inc. Announce Co . . . Altor is distinctively positioning its immunotherapeutic platform to be employed as the backbone therapy in next-generation combination immunotherapy approaches For more information, please visit http: www altorbioscience com
Altor BioScience - Crunchbase Company Profile Funding Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases
Altor BioScience 2025 Company Profile: Valuation, Investors . . . Altor BioScience has raised $119M Who are Altor BioScience’s investors? Gates Foundation , Hamilton Lane , JSD Capital , National Cancer Institute, and National Heart, Lung, and Blood Institute are 5 of 11 investors who have invested in Altor BioScience
Altor Bioscience Corporation | LinkedIn Altor Bioscience Corporation | 272 followers on LinkedIn Altor has developed a unique proprietary technology for producing biologically active, soluble TCR molecules in a single-chain format
Anktiva’s tortuous journey ends | ApexOnco - Clinical Trials . . . Formally the FDA approval was granted to Anktiva’s originator, Altor Bioscience, an entity acquired by an ImmunityBio legacy company in 2017 ImmunityBio is now capitalised at around $4bn, a valuation exceeding the $2 2bn of CG Oncology, which floated in January and is the next NMIBC player to watch
Altor BioScience Corporation Announces FDA Fast Track . . . MIRAMAR, Fla --(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, announced today that it has received Fast Track designation from the U S Food and Drug Administration (FDA) for its investigational interleukin-15 (IL-15) agonist complex, ALT
ALT-803, an IL-15 superagonist, in combination with . . . - PubMed Altor BioScience (a NantWorks company), National Institutes of Health, and Medical University of South Carolina Hollings Cancer Center ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial